{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T00:54:14Z","timestamp":1792457654374,"version":"4.5.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2021,11,11]],"date-time":"2021-11-11T00:00:00Z","timestamp":1636588800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,11,11]],"date-time":"2021-11-11T00:00:00Z","timestamp":1636588800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002957","name":"Technische Universit\u00e4t Dresden","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002957","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Thromb Thrombolysis"],"published-print":{"date-parts":[[2022,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Since direct oral anticoagulants (DOAC) are administered frequently to an elderly, co-morbid population, medical emergencies including trauma, acute bleeding or organ failure are not uncommon. In these situations, the type, dosage or the time of last intake of anticoagulants is often unknown and single substance analysis by functional tests is only possible if the substance contained in the sample is known. A reliable and validated toxicology screen of DOAC and argatroban would be helpful inform not only attending physicians in the emergency department but also law enforcement and courts of justice. After precipitation with acetone, HPLC separation was achieved on a Phenomenex Luna Pentafluorophenyl Colum using acetonitrile\u2013water (90:10, v\/v) as mobile phase system. Detection was performed using a 3200 Q Trap mass spectrometer (AB Sciex). For analysis MRM Scans (MS\/MS) with positive ionization were chosen. The method was validated for blank serum as the matrix of choice. Limits of detection are between 0.5 and 1.0\u00a0ng\/mL, limits of quantification are between 1.9 and 3.6\u00a0ng\/mL and recoveries are above 60%. The applicability of the method was demonstrated by the determination of DOAC in body fluids from forensic cases and in therapeutic drug monitoring. The rapid simultaneous detection and quantification of apixaban, argatroban, dabigatran etexilate, dabigatran, edoxaban and rivaroxaban in body fluids by HPLC\u2013MS\/MS closes an important gap in emergency toxicology.<\/jats:p>","DOI":"10.1007\/s11239-021-02596-z","type":"journal-article","created":{"date-parts":[[2021,11,11]],"date-time":"2021-11-11T06:02:34Z","timestamp":1636610554000},"page":"777-787","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Development and validation of an analytical method for the determination of direct oral anticoagulants (DOAC) and the direct thrombin-inhibitor argatroban by HPLC\u2013MS\/MS"],"prefix":"10.1007","volume":"53","author":[{"given":"Lea","family":"Br\u00fcckner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6983-9993","authenticated-orcid":false,"given":"Jan","family":"Beyer-Westendorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Tiebel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rg","family":"Pietsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,11,11]]},"reference":[{"key":"2596_CR1","unstructured":"Kemkes-Matthes B (2006) Argatroban. Arzneimitteltherapie 24:305\u2013307. https:\/\/www.arzneimitteltherapie.de\/heftarchiv\/2006\/09\/argatroban-die-arzneimitteltherapie-im-internet-http-www-arzneimitteltherapie-de.html. Accessed 18 February 2021"},{"key":"2596_CR2","unstructured":"Stiefelhagen P (2013) Klinischer alltag best\u00e4tigt studienergebnisse mit rivaroxaban. Arzneimitteltherapie 31. https:\/\/www.arzneimitteltherapie.de\/heftarchiv\/2013\/11\/klinischer-alltag-bestatigt-studienergebnisse-mit-rivaroxaban.html. Accessed 25 May 2021"},{"key":"2596_CR3","unstructured":"Quante M, Schofer MD, Musch A (2009) Dabigatran. Arzneimitteltherapie 27:71\u201378. https:\/\/www.arzneimitteltherapie.de\/heftarchiv\/2009\/03\/dabigatran-orale-antikoagulation-mit-direktem-thrombin-inhibitor.html. Accessed 25 May 2021"},{"key":"2596_CR4","unstructured":"Tippmann ME (2011) Apixaban \u00fcberzeugt in der VTE-Prophylaxe. Arzneimitteltherapie 29. https:\/\/www.arzneimitteltherapie.de\/heftarchiv\/2011\/10\/apixaban-uberzeugt-in-der-vte-prophylaxe.html. Accessed 18 February 2021"},{"key":"2596_CR5","unstructured":"Stiefelhagen P (2015) NOAK verspricht mehr Sicherheit bei gleich guter Wirksamkeit. Arzneimitteltherapie 33. https:\/\/www.arzneimitteltherapie.de\/heftarchiv\/2015\/11\/noak-verspricht-mehr-sicherheit-bei-gleich-guter-wirksamkeit.html. Accessed 18 February 2021"},{"key":"2596_CR6","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/s11239-016-1446-0","volume":"43","author":"A Zirlik","year":"2017","unstructured":"Zirlik A, Bode C (2017) Vitamin K antagonists: relative strengths and weaknesses vs. direct oral anticoagulants for stroke prevention in patients with atrial fibrillation. J Thromb Thrombolysis 43:365\u2013379. https:\/\/doi.org\/10.1007\/s11239-016-1446-0","journal-title":"J Thromb Thrombolysis"},{"key":"2596_CR7","unstructured":"Mende A (2017) DOAK zur\u00fcckhaltend einsetzen. Pharmazeutische Zeitung. https:\/\/www.pharmazeutische-zeitung.de\/ausgabe-032017\/doak-zurueckhaltend-einsetzen\/. Accessed 18 February 2021"},{"key":"2596_CR8","unstructured":"Siegert G, Liebscher K, Beyer-Westendorf J, Gehrisch S, Platzbecker U, Scholz U (2014) Labordiagnostik unter Antikoagulation. \u00c4rzteblatt Sachsen. https:\/\/www.aerzteblatt-sachsen.de\/pdf\/sax14_427.pdf#search=%22Antikoagulation%22&view=%22fit%22. Accessed 6 June 2021"},{"key":"2596_CR9","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1097\/FTD.0000000000000744","volume":"42","author":"M Zhang","year":"2020","unstructured":"Zhang M, Moore GA, Chin PKL (2020) Simultaneous determination of dabigatran, rivaroxaban, and apixaban in human plasma by liquid chromatography\/tandem MS spectrometry. Ther Drug Monit 42:473\u2013480. https:\/\/doi.org\/10.1097\/FTD.0000000000000744","journal-title":"Ther Drug Monit"},{"key":"2596_CR10","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.jchromb.2012.02.041","volume":"893\u2013894","author":"JM Rhea","year":"2012","unstructured":"Rhea JM et al (2012) Development of a fast and simple liquid chromatography-tandem mass spectrometry method for the quantitation of argatroban in patient plasma. J Chromatogr B 893\u2013894:168\u2013172. https:\/\/doi.org\/10.1016\/j.jchromb.2012.02.041","journal-title":"J Chromatogr B"},{"key":"2596_CR11","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1007\/s11239-019-02030-5","volume":"49","author":"R Siriez","year":"2020","unstructured":"Siriez R, Alpan L, Elasaad K, Devel P, Laloy J, Dogne JM, Douxfils J (2020) Importance of measuring pharmacologically active metabolites of edoxaban: development and validation of an ultra-high performance liquid chromatography coupled with a tandem mass spectrometry method. J Thromb Thrombolysis 49:395\u2013403. https:\/\/doi.org\/10.1007\/s11239-019-02030-5","journal-title":"J Thromb Thrombolysis"},{"key":"2596_CR12","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1111\/jth.12702","volume":"12","author":"EMH Schmitz","year":"2014","unstructured":"Schmitz EMH, Boonen K, van den Heuvel JA, van Dongen LJ, Schellings MWM, Emmen JMA, van der Graf F, Brunsveld L, van de Kerkhof D (2014) Determination of dabigatran, rivaroxaban and apixaban by ultra-performance liquid chromatography\u2014tandem mass spectrometry (UPLC-MS\/MS) and coagulation assays for therapy monitoring of novel direct oral anticoagulants. J Thromb Haemost 12:1636\u20131646. https:\/\/doi.org\/10.1111\/jth.12702","journal-title":"J Thromb Haemost"},{"key":"2596_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2020.113109","author":"F Gouveia","year":"2020","unstructured":"Gouveia F, Bicker J, Santos J, Rocha M, Alves G, Falc\u00e3o A, Fortuna A (2020) Development, validation and application of a new HPLC-DAD method for simultaneous quantification of apixaban, dabigatran, edoxaban and rivaroxaban in human plasma. J Pharm Biomed Anal. https:\/\/doi.org\/10.1016\/j.jpba.2020.113109","journal-title":"J Pharm Biomed Anal"},{"key":"2596_CR14","first-page":"73","volume":"6","author":"P Ravisankar","year":"2018","unstructured":"Ravisankar P, Srikanth D, Venkateswara Reddy C, Raghavendra Rao P, Srinivasa Babu P (2018) Development and validation of UV spectrophotometric method for the determination of edoxaban tosylate monohydrate in pharmaceutical dosage form. Indian J Res Pharm Biotech 6:73\u201378","journal-title":"Indian J Res Pharm Biotech"},{"key":"2596_CR15","doi-asserted-by":"publisher","first-page":"8150","DOI":"10.5281\/zenodo.2526031","volume":"7","author":"PA Malode","year":"2017","unstructured":"Malode PA, Pendhari SS, Ghuge BS, Anantwar SP (2017) Development and validation of simple UV spectrophotometric method for the determination of apixaban in api and its bulk dosage form. Indo Am J Pharm Res 7:8150\u20138158. https:\/\/doi.org\/10.5281\/zenodo.2526031","journal-title":"Indo Am J Pharm Res"},{"key":"2596_CR16","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.chemosphere.2017.11.036","volume":"193","author":"M Yassine","year":"2018","unstructured":"Yassine M et al (2018) Photodegradation of novel oral anticoagulants under sunlight irradiation in aqueous matrices. Chemosphere 193:329\u2013336. https:\/\/doi.org\/10.1016\/j.chemosphere.2017.11.036","journal-title":"Chemosphere"},{"key":"2596_CR17","first-page":"1215","volume":"12","author":"K Bhavyasri","year":"2020","unstructured":"Bhavyasri K, Dhanalakshmi Ch, Sumakanth M (2020) Development and validation of ultra violet-visible spectrophotometric method for estimation of rivaroxaban in spiked human plasma. J Pharm Sci Res 12:1215\u20131219","journal-title":"J Pharm Sci Res"},{"key":"2596_CR18","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.forsciint.2006.05.021","volume":"165","author":"FT Peters","year":"2007","unstructured":"Peters FT, Drummer OH, Musshoff F (2007) Validation of new methods. Forensic Sci Int 165:216\u2013224. https:\/\/doi.org\/10.1016\/j.forsciint.2006.05.021","journal-title":"Forensic Sci Int"},{"key":"2596_CR19","unstructured":"Schmitt G, Herbold M, Peters F (2004) Methodenvalidierung im forensisch-toxikologischen Labor: Auswertung von Validierungsdaten nach den Richtlinien der GTFCh mit VALISTAT. Arvecon, Walldorf"},{"key":"2596_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-020-02915-5","author":"M Schulz","year":"2020","unstructured":"Schulz M, Schmoldt A, Andresen-Streichert H, Iwersen-Bergmann S (2020) Revisited: therapeutic and toxic blood concentrations of more than 1100 drugs and other xenobiotics. Crit Care. https:\/\/doi.org\/10.1186\/s13054-020-02915-5","journal-title":"Crit Care"}],"container-title":["Journal of Thrombosis and Thrombolysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-021-02596-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11239-021-02596-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-021-02596-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,28]],"date-time":"2022-05-28T05:06:16Z","timestamp":1653714376000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11239-021-02596-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,11]]},"references-count":20,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["2596"],"URL":"https:\/\/doi.org\/10.1007\/s11239-021-02596-z","relation":{},"ISSN":["0929-5305","1573-742X"],"issn-type":[{"value":"0929-5305","type":"print"},{"value":"1573-742X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,11]]},"assertion":[{"value":"20 October 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"L. Br\u00fcckner and J. Pietsch declare that they have no known financial interests or personal relationships that could influence the work reported in this paper. J. Beyer-Westendorf received personal honoraria and institutional research support from the DOAC manufacturers Bayer, Daiichi Sankyo and Pfizer during the last 5\u00a0years. O. Tiebel received personal honoraria from the DOAC manufacturer Daiichi Sankyo.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}